LifeMD vs Shed: Genetic Factors & GLP-1 Selection

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

LifeMD and Shed are popular telehealth platforms offering GLP-1 medications for weight management and metabolic health. Both provide remote consultations and home delivery, but individual response to GLP-1 therapy varies significantly based on genetic predispositions in key metabolic pathways. Understanding your unique genetic profile can support a more informed conversation with your provider.

Choosing between telehealth GLP-1 providers isn't just about cost or convenience—it's about finding a medication and dosing strategy aligned with your individual biology. Precision-guided therapy, informed by genetic context and biomarker assessment, helps providers tailor treatment rather than applying a one-size approach. This article explores how to evaluate your options with clinical evidence and personalization in mind.

Understanding LifeMD and Shed: Platform Structure and Reach

LifeMD operates as a multi-specialty telehealth platform with licensed providers across multiple states, offering semaglutide and tirzepatide prescriptions alongside lifestyle coaching. Shed focuses narrowly on weight loss GLP-1s with a smaller provider network but emphasizes data-driven dosing and frequent follow-ups. Both require telehealth consultations; neither can prescribe without medical evaluation.

Platform reach and state licensure vary. LifeMD partners with traditional pharmacies and fulfillment centers, while Shed uses compounding partners for some formulations. Costs typically range from $129-$369/mo monthly depending on medication and dose, with initial consultation fees of $25–$50. Eligibility requires BMI ≥27 with comorbidity or ≥30 baseline, though criteria differ slightly between platforms.

Medication Options, Dosing Protocols, and Individual Response Variation

Both platforms prescribe semaglutide and tirzepatide, the two most widely studied GLP-1 receptor agonists. Response rates to semaglutide hover near 70% for meaningful weight loss (≥5% of body weight), while tirzepatide shows higher response (around 85%) due to dual GIP-receptor activation. However, individual outcomes depend on genetic variation in GLP1R, GIPR, FTO, and MC4R pathways—not just medication choice alone.

Factor	LifeMD	Shed	Clinical Significance
Primary GLP-1s offered	Semaglutide, tirzepatide	Semaglutide, tirzepatide	Both use standard formulations; no major difference in active drug
Typical starting dose protocol	Variable per provider	Structured titration schedule	Consistent dosing may reduce side effects; individual tolerance varies by genetics
Genetic predisposition screening	Not routinely offered	Not routinely offered	Variants in GLP1R and GIPR affect metabolic response and tolerability
Follow-up frequency	Monthly or quarterly	Biweekly to monthly	More frequent monitoring may optimize titration for responders vs. non-responders

Cost, Insurance, and Financial Accessibility

LifeMD typically charges $50–$100 per consultation and $250–$350 monthly for compounded or branded medications, with limited insurance coverage acceptance. Shed charges $25–$75 per visit and $200–$300 monthly, also accepting limited insurance. Both offer autopay discounts of 10–20%. Neither platform guarantees insurance reimbursement; most patients pay out-of-pocket.

PlexusDx compounded semaglutide starts at $149 monthly, and tirzepatide at $249 monthly—with microdose GLP-1 protocols available at $129 monthly for eligible patients. Consultation and genetic testing costs vary; the Precision Peptide Genetic Test ($99 add-on or $298 standalone) may help inform medication selection, though it predicts predispositions, not guaranteed outcomes.

Medical Evaluation, Safety Monitoring, and Who This Treatment Applies To

LifeMD and Shed both require baseline screening: BMI assessment, medical history review, and contraindication screening (thyroid cancer history, pancreatitis, severe kidney disease exclude eligibility). Shed includes more structured weight-loss outcome tracking; LifeMD offers broader metabolic testing. Neither platform replaces in-person endocrinology care for complex cases or existing comorbidities. GLP-1 therapy is not appropriate for pregnant individuals, those with medullary thyroid carcinoma family history, or multiple endocrine neoplasia type 2.

Nausea and gastrointestinal side effects affect 40–50% of users in early weeks; genetic variation in serotonin signaling (affected by FTO and MC4R variants) may influence tolerance. Rare serious events—pancreatitis, gallbladder disease, retinal complications—require medical oversight. A qualified provider should interpret any genetic predisposition findings and adjust monitoring accordingly.

Genetic Predispositions and Metabolic Pathways: A Framework for Personalization

GLP-1 response is not random. Variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) predict subtle differences in satiety signaling, appetite suppression, and metabolic efficiency. Individuals carrying certain FTO risk alleles may experience slower weight loss with semaglutide alone; GIPR variants correlate with stronger response to tirzepatide's dual mechanism. Understanding your genetic landscape can guide the right medication choice and dosing approach.

Neither LifeMD nor Shed routinely orders genetic pathway testing. PlexusDx's Precision Peptide Genetic Test reveals predispositions in these four key variants, helping providers understand whether semaglutide, tirzepatide, or a dual-compound approach like GLP-Squared may be better suited to your individual biology. Genetic context should always be interpreted by a qualified healthcare provider and combined with clinical assessment—not used as a standalone predictor of exact medication response.

How PlexusDx Supports a More Personalized Approach

PlexusDx integrates genetic predisposition assessment with compounded GLP-1 prescribing, offering insights into individual variation in peptide pathways. The Precision Peptide Genetic Test may help provide context for whether semaglutide, tirzepatide, or a dual-compound regimen aligns with your unique metabolic profile. This approach supports a more informed conversation with your provider about which medication and dosing strategy to try first.

The Precision Peptide Genetic Test examines predispositions in GLP1R, GIPR, FTO, and MC4R pathways—revealing how your genetic makeup may influence satiety signaling, weight loss efficiency, and tolerability. Variants in these genes correlate with response patterns in clinical studies, but genetic predisposition is not a guarantee of exact medication outcome. Results should be interpreted with a qualified healthcare provider as one data point among many.

If you're considering GLP-1 therapy, understanding your genetic predispositions can support a more personalized discussion with your provider about whether to start with semaglutide, tirzepatide, or PlexusDx's GLP-Squared dual compound. Combined with biomarker assessment and your clinical history, genetic context helps optimize medication selection and dosing strategy—moving toward truly precision wellness rather than trial-and-error treatment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What's the main difference between LifeMD and Shed for GLP-1 treatment?

LifeMD is a multi-specialty telehealth platform offering various medications alongside GLP-1s; Shed focuses exclusively on weight loss with structured dosing protocols. Both prescribe semaglutide and tirzepatide but differ in follow-up frequency and cost models. Provider expertise varies within each platform.

Do LifeMD and Shed screen for genetic factors that affect GLP-1 response?

Neither LifeMD nor Shed routinely orders genetic predisposition testing for GLP-1 pathways. Both rely on standard medical evaluation. PlexusDx offers the Precision Peptide Genetic Test, which reveals predispositions in key metabolic genes—providing additional context for personalized medication selection.

Which platform is more affordable: LifeMD, Shed, or PlexusDx compounded options?

LifeMD and Shed typically cost $200–$350 monthly; PlexusDx compounded semaglutide starts at $179 and tirzepatide at $229 monthly, with microdose protocols at $129. Cost depends on medication, dose, and whether genetic testing is added. Compare based on your prescription and coverage needs.

Are there safety differences between LifeMD, Shed, and compounded GLP-1s?

All GLP-1 therapies carry similar risks: nausea, GI side effects, and rare pancreatitis. Medical evaluation and monitoring are essential with any platform. Compounded medications from 503A pharmacies undergo strict quality controls. Choose a provider that offers appropriate baseline screening and follow-up support.

How can genetic testing help me choose between semaglutide and tirzepatide?

Genetic variants in GLP1R, GIPR, and FTO correlate with response patterns; GIPR carriers may benefit more from tirzepatide's dual mechanism. The Precision Peptide Genetic Test reveals these predispositions, supporting a more informed conversation with your provider. Genetic context, combined with your medical history, helps guide medication sele...

LifeMD vs Shed: How Genetic Insights Shape Your GLP-1 Choice

LifeMD and Shed both offer telehealth GLP-1 access, but medication response varies by individual genetic pathways.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →